Exelixis, Inc. EXEL

Company Overview

Exelixis, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oncology therapeutics. The company operates primarily in the biopharmaceutical industry, with a strategic emphasis on targeted cancer therapies and immuno-oncology combinations. Exelixis generates the majority of its revenue from sales of its lead oncology drug, CABOMETYX (cabozantinib), as well as from collaboration revenues tied to licensing and development partnerships. The company serves oncologists, hospitals, specialty pharmacies, and healthcare systems primarily in the treatment of renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and other advanced solid tumors.

The company was founded in 1994 and initially focused on genomics and drug discovery technologies before evolving into a commercial-stage oncology company. Exelixis’ transition accelerated following the clinical and commercial success of cabozantinib-based therapies. The company has established a differentiated position through its expertise in tyrosine kinase inhibitor development, broad clinical trial programs, and strategic collaborations with major pharmaceutical companies. Its business model combines internally developed oncology assets with external licensing agreements designed to expand therapeutic indications and geographic reach.